RVLP News and Press, RVL Pharmaceuticals plc From 09/06/23

RVL Pharmaceuticals (NASDAQ: RVLP) is a specialty pharmaceutical company focusing on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution), 0.1%, available by prescription for the treatment of acquired blepharoptosis (low-lying eyelid(s)) in adults. “UPNEEQ(...

RVL Pharmaceuticals (NASDAQ: RVLP) , a specialty pharmaceutical company focused on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution) (“UPNEEQ”), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults, will be represented...

BRIDGEWATER, N.J., Aug. 23, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced that Brian Markison, Chief Executive Officer, will participate in a fireside chat and host 1x1 inve...

For the quarter ended June 30, 2023, RVLP reported net sales of $8.3 million and operating expenses of $14.4 million, down 2% and 32%, respectively, compared to the prior year period; this strategy is designed to extend cash runway for future business development and changes in the company’...

RVL Pharmaceuticals (NASDAQ: RVLP) , a specialty pharmaceutical company focused on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution) (“UPNEEQ”), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults, is featured in a re...

2023-08-16 09:04:41 ET RVL Pharmaceuticals ( NASDAQ: RVLP ) has priced an offering of its ordinary shares to raise $5 million. The company said it will offer 11,870,846 shares at $0.4212 apiece. The company also agreed to issue unregistered series A-1 warrants to...

BRIDGEWATER, N.J., Aug. 16, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the tr...

2023-08-14 15:23:04 ET RVL Pharmaceuticals plc (RVLP) Q2 2023 Earnings Conference Call August 14, 2023, 08:30 AM ET Company Participants Lisa Wilson - In-Site Communications, IR Brian Markison - Chief Executive Officer James Schaub - Chief Operating Officer M...

RVL Pharmaceuticals (NASDAQ: RVLP) is a specialty pharmaceutical company focused on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. The company today announced financial resu...

2023-08-14 06:54:42 ET RVL Pharmaceuticals plc press release ( NASDAQ: RVLP ): Q2 GAAP EPS of -$0.24 misses by $0.12 . Revenue of $8.26M (-2.2% Y/Y) misses by $1.99M . At June 30, 2023, the Company had cash and cash equivalents of $19.2 million and senior secur...